RenovoRx Retained Earnings (Accumulated Deficit) 2020-2024 | RNXT

RenovoRx retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

RenovoRx Retained Earnings (Accumulated Deficit) 2020-2024 | RNXT

RenovoRx retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$129.4B
Gilead Sciences (GILD)$121.9B
Bristol Myers Squibb (BMY)$111B
CSL (CSLLY)$91.9B
Regeneron Pharmaceuticals (REGN)$90.6B
GSK (GSK)$76B
Argenex SE (ARGX)$35.4B
Alnylam Pharmaceuticals (ALNY)$35.1B
BioNTech SE (BNTX)$25.7B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.6B
BeiGene (BGNE)$20.1B
Moderna (MRNA)$19.3B
Incyte (INCY)$15.9B
Genmab (GMAB)$15.3B
Insmed (INSM)$12.8B
Vaxcyte (PCVX)$12.8B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.5B
Exelixis (EXEL)$10.2B
QIAGEN (QGEN)$10.1B
Revolution Medicines (RVMD)$9.9B
Exact Sciences (EXAS)$9.9B
Intra-Cellular Therapies (ITCI)$9.6B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.1B
Ascendis Pharma (ASND)$7.7B